Technical Analysis for ORMP - Oramed Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical ORMP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| New Downtrend | Bearish | -0.45% | |
| Outside Day | Range Expansion | -0.45% | |
| Wide Bands | Range Expansion | -0.45% | |
| Wide Bands | Range Expansion | -4.91% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Spinning Top | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Fell Below 20 DMA | Bearish | -5.01% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 5% | 3 days ago | |
| Fell Below Previous Day's Low | 3 days ago | |
| Down 3% | 3 days ago | |
| Down 2 % | 3 days ago | |
| Down 1% | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/01/2020
Oramed Pharmaceuticals Inc. Description
Oramed Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's products primarily comprise ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone that is in per-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Jerusalem, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Pharmaceutical Industry Diabetes Medication Gastrointestinal Dosage Forms Endocrine System Insulin Polyp Peptides Salem Peptide Hormones Treatment Of Diabetes Rusal Glucagon Like Peptide 1 Integrated Security Tablet Pharmaceutical Solutions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.7 |
| 52 Week Low | 2.4 |
| Average Volume | 663,728 |
| 200-Day Moving Average | 4.20 |
| 50-Day Moving Average | 6.78 |
| 20-Day Moving Average | 9.83 |
| 10-Day Moving Average | 10.01 |
| Average True Range | 0.90 |
| ADX | 48.96 |
| +DI | 21.48 |
| -DI | 22.25 |
| Chandelier Exit (Long, 3 ATRs ) | 9.00 |
| Chandelier Exit (Short, 3 ATRs ) | 9.09 |
| Upper Bollinger Band | 11.76 |
| Lower Bollinger Band | 7.89 |
| Percent B (%b) | 0.26 |
| BandWidth | 39.37 |
| MACD Line | 0.74 |
| MACD Signal Line | 1.12 |
| MACD Histogram | -0.3801 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.31 | ||||
| Resistance 3 (R3) | 10.32 | 9.88 | 10.07 | ||
| Resistance 2 (R2) | 9.88 | 9.52 | 9.87 | 9.99 | |
| Resistance 1 (R1) | 9.39 | 9.30 | 9.17 | 9.38 | 9.92 |
| Pivot Point | 8.95 | 8.95 | 8.84 | 8.94 | 8.95 |
| Support 1 (S1) | 8.46 | 8.59 | 8.24 | 8.45 | 7.90 |
| Support 2 (S2) | 8.02 | 8.37 | 8.01 | 7.83 | |
| Support 3 (S3) | 7.53 | 8.02 | 7.75 | ||
| Support 4 (S4) | 7.52 |
